cellvie, a company based in Houston, Texas, is developing a mitochondrial transplantation therapy to help reduce the damage caused by ischemia-reperfusion injury. The treatment involves delivering isolated mitochondria to cells that are affected by ischemia to help mitigate the dysfunctional metabolism that contributes to cell death in that context.
The treatment is designed to improve outcomes after ischemic events, such as myocardial infarcts, and may also help to improve graft function in cases of heart or kidney transplantation. At present, the treatment involves harvesting mitochondria from tissue or cell samples using an automated system and then delivering them in a vector that allows for endocytosis and incorporation by target cells. The company recently won the MedTech Innovator Value Award.